Vaccine for Ebola virus

One of the world’s deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.

Read more

Potential new target for multiple sclerosis therapy

Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.

Read more

Stem Cells from Hair Follicles May Help “Grow” New Blood Vessels

For a rich source of stem cells to be engineered into new blood vessels or skin tissue, clinicians may one day look no further than the hair on their patients’ heads, according to new research published earlier this month by University at Buffalo engineers.

Read more

FDA Seeks Civil Penalties from Calif. Device Maker

The U.S. Food and Drug Administration (FDA) today announced it is seeking a 2.2 million dollar penalty against a California hearing aid manufacturer for violations of federal law, including manufacturing standards violations and the failure to inform the FDA of a change in an outside supplier or vendor, which may have exposed recipients of the devices to unnecessary health risks. Read more

Scientists find a key culprit in stroke brain cell damage

Researchers have identified a key player in the killing of brain cells after a stroke or a seizure. The protein asparagine endopeptidase (AEP) unleashes enzymes that break down brain cells’ DNA, scientists at Emory University School of Medicine have found.

Read more

Rectal artemisinins rapidly eliminate malarial parasites

Artemisinin-based suppositories can help ‘buy time’ for malaria patients who face a delay in accessing effective, injectable antimalarials, according to research published in the online open access journal BMC Infectious Diseases.

Read more

Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770

The Cystic Fibrosis Foundation announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.

Read more

FDA Warns Consumers about Total Body Formula and Total Body Mega Formula

The liquid dietary supplement products may cause severe adverse reactions, including significant hair loss, muscle cramps, diarrhea, joint pain and fatigue.

Original post by Food and Drug Administration Press Releases

FDA Identifies First Steps in Requirements for Safety Plans for convinced Drugs and Biologics

The U.S. Food and Drug Administration has identified 25 drugs and biologic products that will be mandatory to submit safety plans called Risk Evaluation and Mitigation Strategy (REMS), the FDA said in a Federal Register notice published today. Read more

FDA Makes Recommendations on Medical Devices That Treat Blocked Heart Arteries

U.S. Food and Drug Administration Commissioner Andrew C. von Eschenbach today announced that the agency has issued draft guidelines to aid the development, checking and manufacture of coronary drug-eluting stents, devices used to treat blocked heart arteries. Read more

Next Page »